Accendra Health Inc/Va/ (ACH) Stock Price & Analysis
Accendra Health Inc/Va/ (ACH) rose 4.71% to USD 2.67 as of June 10, 2026 at 00:53 UTC, according to Nexqual real-time market data.
ACH last closed at USD 2.55; the session ranged USD 2.54–2.72 on volume of 390,074 shares. Market capitalization is $204.48M, with a 52-week range of USD 1.84–9.55 (NYQ). Source: Nexqual, June 10, 2026 at 00:53 UTC.
Key Statistics (as of June 10, 2026 at 00:53 UTC)
| Price | USD 2.67 |
|---|---|
| Change | ▲ 4.71% (up) |
| Previous Close | USD 2.55 |
| Open | USD 2.54 |
| Day Range | USD 2.54 – 2.72 |
| 52-Week Range | USD 1.84 – 9.55 |
| Volume | 390,074 shares |
| Market Cap | $204.48M |
| Exchange | NYQ |
Technical Analysis (ACH)
Nexqual's technical model rates ACH "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:53 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.14 (neutral) |
| vs SMA50 | Below (USD 3.05) |
| MACD | -0.14 (negative) |
Analyst Ratings (ACH)
Wall Street analysts rate ACH "Hold" based on 5 analysts, with a mean price target of USD 4.49 (range USD 2.7–6), per Nexqual as of June 10, 2026 at 00:53 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 4.49 |
| High Target | USD 6 |
| Low Target | USD 2.7 |
| Buy / Hold / Sell | 2 / 2 / 2 |
Earnings (ACH)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $627.37M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.04 vs est -0.1 ▲ beat |
| 2025-12-31 | USD 0.21 vs est 0.22 ▼ miss |
| 2025-09-30 | USD 0.25 vs est 0.23 ▲ beat |
| 2025-06-30 | USD 0.26 vs est 0.28 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Financials & Fundamentals (ACH)
| Total Revenue | $2.72B |
|---|---|
| Revenue Growth (YoY) | -6.80% |
| Gross Margin | +45.95% |
| Operating Margin | -1.02% |
| Profit Margin | -39.84% |
| ROE | -198.35% |
| Current Ratio | 0.49 |
| Total Cash | $338.49M |
| Total Debt | $2.17B |
| Free Cash Flow | $650.28M |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Financial Health Score (ACH)
Nexqual rates Accendra Health Inc/Va/'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:53 UTC.
| Growth | Critical — Revenue -74% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 46%, operating -1% |
| Balance Sheet | Mixed — $338M cash vs $2.17B debt |
| Cash Flow | Strong — FCF $650M, 24% margin |
| Efficiency | Critical — ROE -198%, ROA 1.6% |
Ownership (ACH)
| Insider Ownership | +7.71% |
|---|---|
| Institutional Ownership | +85.89% |
| Shares Outstanding | 76.58M |
| Float | 56.17M |
| Short % of Float | +9.43% |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Leadership (ACH)
Accendra Health Inc/Va/ is led by Edward A. Pesicka (age 57), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:53 UTC.
| President, CEO & Director | Edward A. Pesicka (age 57) |
|---|---|
| Executive VP, CFO & Corporate Treasurer | Jonathan A. Leon (age 58) |
| Executive VP & COO | Perry A. Bernocchi (age 66) |
| Vice President of Strategy of Corporate Development, & Investor Relations | Will Parrish |
| Chief Products Officer | Colin Bain |
Major Backers & Investors (ACH)
Notable institutional backers of Accendra Health Inc/Va/ include Coliseum Capital Management, Llc, Charles Schwab Investment Management, Inc., Bank of America Corporation, according to Nexqual as of June 10, 2026 at 00:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Coliseum Capital Management, Llc | 17.11% |
| Charles Schwab Investment Management, Inc. | 4.75% |
| Bank of America Corporation | 4.45% |
| Invenomic Capital Management, LP | 4.4% |
| Shaw D.E. & Co., Inc. | 4.32% |
| Charles Schwab | 3.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.82% |
| BlackRock | 10.1% |
| Dimensional Fund Advisors | 3.4% |
| Geode Capital | 2.4% |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
From Accendra Health Inc/Va/'s Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States.
- It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services.
- The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CHA | Chagee Holdings Limited | USD 10.9 | ▼ 5.55% |
| ABG | Asbury Automotive Group Inc | USD 201.04 | ▲ 5.27% |
| CYD | China Yuchai International Limi | USD 53.45 | ▼ 5.83% |
| AFG | American Financial Group, Inc. | USD 131.28 | ▼ 0.89% |
| AHRT | AH Realty Trust, Inc. | USD 6.85 | ▲ 1.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:53 UTC. This page is informational and not investment advice.